A Clinical Study of AK120 in Adolescents With Moderate-to-severe Atopic Dermatitis

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

198

Participants

Timeline

Start Date

January 23, 2025

Primary Completion Date

July 10, 2027

Study Completion Date

July 10, 2027

Conditions
Atopic Dermatitis
Interventions
DRUG

Placebo

placebo subcutaneous injection Q2W until week 46.

DRUG

placebo

placebo subcutaneous injection Q3W until week 45.

Trial Locations (28)

Unknown

The Second Affiliated Hospital of Wannan Medical College, Wuhu

Peking University People's Hospital, Beijing

Chongqing Traditional Chinese Medicine Hospital, Chongqing

The First Affiliated Hospital of Chongqing Medical University, Chongqing

Dongguan People's Hospital, Dongguan

Dermatology Hospital of Southern Medical University, Guangzhou

Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou

The First Affiliated Hospital of Jinan University, Guangzhou

The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou

Jiangmen Central Hospital, Jiangmen

The University of Hong Kong - Shenzhen Hospital, Shenzhen

The Third People's Hospital of Zhuhai, Zhuhai

Liuzhou Worker's Hospital, Liuzhou

Jinzhou Central Hospital, Jinzhou

Tongji Hospital, Wuhan

Hunan Children's Hospital, Changsha

XiangYa Hospital CentralSouth University, Changsha

Affiliated Hospital of Jiangsu University, Zhenjiang

Dermatology Hospital of Jiangxi Province, Nanchang

Shandong Provincial Dermatology Hospital, Jinan

Jining First People's Hospital, Jining

Huashan Hospital, Fudan University, Shanghai

Longhua Hospital Shanghai University of Traditional Chinese Medicine, Shanghai

Shanghai Skin Disease Hospital, Shanghai

The First Affiliated Hospital of Xi'an Jiao Tong University, Xi’an

Sichuan Provincial People's Hospital, Chengdu

The First Affiliated Hospital of Kunming Medical University, Kunming

The First Hospital of Jiaxing, Jiaxing

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Akeso

INDUSTRY

NCT06767540 - A Clinical Study of AK120 in Adolescents With Moderate-to-severe Atopic Dermatitis | Biotech Hunter | Biotech Hunter